undamentalytics Newsletter

Levine Mark S.: insider trades

Officer at Immunovant, Inc. No open-market purchases and 17 sales not made under a pre-set plan, reported from January 27, 2023 to November 22, 2024.

What happened after Levine Mark S.’s sales?

After their sales, the shares moved −31.7% against the index over 12 months on average (a negative figure means selling was the right call); 77% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Levine Mark S.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 17 −2.0% −2.7% 71% 2 — — Not enough years
Sales, 12 months after the report 17 −31.7% −52.7% 77% 2 — — Not enough years
Sales, 12 months after the trade 17 −31.1% −51.5% 77% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Immunovant, Inc. IMVT Chief Legal Officer017January 27, 2023November 22, 2024

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
November 22, 2024November 20, 2024 IMVT Sale $92,892 −23.2%−25.9%−25.5%
October 25, 2024October 23, 2024 IMVT Sale $128,780 −30.8%−35.6%−48.6%
October 18, 2024October 16, 2024 IMVT Sale $82,339 −25.2%−52.7%−50.8%
August 23, 2024August 21, 2024 IMVT Sale $104,976 −22.6%−70.9%−70.2%
July 26, 2024July 24, 2024 IMVT Sale $111,456 −2.7%−62.2%−59.2%
July 19, 2024July 17, 2024 IMVT Sale $74,382 −0.5%−50.4%−55.3%
May 24, 2024May 22, 2024 IMVT Sale $96,125 +5.3%−60.4%−64.7%
April 26, 2024April 24, 2024 IMVT Sale $114,531 −1.8%−53.0%−56.8%
April 19, 2024April 17, 2024 IMVT Sale $285,554 −13.8%−58.4%−53.1%
February 23, 2024February 22, 2024 IMVT Sale $77,144 −29.1%−64.0%−63.6%
January 29, 2024January 26, 2024 IMVT Sale $114,778 −29.2%−66.0%−68.1%
November 24, 2023November 22, 2023 IMVT Sale $106,598 +0.4%−53.0%−50.4%
October 27, 2023October 25, 2023 IMVT Sale $142,349 −6.1%−49.8%−51.6%
August 25, 2023August 24, 2023 IMVT Sale $249,406 +56.5%+21.2%+29.8%
July 27, 2023July 26, 2023 IMVT Sale $84,725 +61.4%+7.6%+14.2%
April 26, 2023April 25, 2023 IMVT Sale $42,892 +29.0%+45.6%+45.8%
January 27, 2023January 26, 2023 IMVT Sale $187,988 −2.0%+88.7%+100.2%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Levine Mark S. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.